Key Market Indicator:
F&G: 52
25.060,90 NASDAQ · 48.619,99 DOW · 6.825,55 S&P · 4.865,99 Gold · 63,63 BRENT

One Community. One Spirit. N#1 Broker.
all asset classes · all possibilities

Switch View
Hedge the Peak | Protect your Profits
© ACCESSWIRE
11.12.2024
ISIN: DE0005664809
Evotec SE
EVT
LISTED
XETR
Evotec SE announces first projects for LAB eN(2) drug discovery accelerator with Novo Nordisk
Article
News Preview
Novo Nordisk and Evotec select three projects from Boston University, Harvard University in collaboration with Mass General Brigham, and Joslin Diabetes Center to be developed within LAB eN² focusing on cardiometabolic diseasesLAB eN² is also expanding, adding Boston Children's Hospital, Boston University, Johns Hopkins University, Joslin...
Themefolio
Profiler
Peergroup
© PR Newswire
10.12.2024
ISIN: SE0020353928
Moberg Pharma AB
MOB
LISTED
STO
Moberg Pharma reports topline data in the North American phase 3 study and will regain rights to MOB-015 in EU
Article
News Preview
STOCKHOLM, Dec. 10, 2024 /PRNewswire/ -- Moberg Pharma AB (OMX: MOB) announces that MOB-015 (topical terbinafine) did not meet the primary endpoint in the phase 3 study using 8 weeks of daily dosing followed by weekly maintenance dosing. The company's focus going forward will be on the effective daily dosing regimen approved in 13 EU countries....
Themefolio
Profiler
Peergroup
© Globe Newswire
10.12.2024
ISIN: DK0060257814
Zealand Pharma A/S
ZEAL
LISTED
CPH
Zealand Pharma announces first participant enrolled in Phase 2b ZUPREME-1 trial of petrelintide in people with overweight or obesity
Article
News Preview
Press Release – No. 12 / 2024...
Themefolio
Profiler
Peergroup
Worth to know
20.10.2025
Short Selling Radar
USA, Europe, Asia
Track Short Selling Activities worldwide
More Info
Knowing what matters
Short sale statistics, hedge fund activities and much more user-friendly information
© BusinessWire
10.12.2024
ISIN: CA23256X4075
Cybin Inc.
HELP
LISTED
NASDAQ
Cybin Announces Poster Presentations at the 2024 American College of Neuropsychopharmacology Annual Meeting, Including CYB003 12-Month Efficacy Results
Article
News Preview
Cybin Inc. (NYSE American:CYBN) (Cboe CA:CYBN) (“Cybin” or the “Company”), a clinical-stage breakthrough neuropsychiatry company committed to revolutionizing mental healthcare by developing new and innovative next-generation treatment options, today announced the presentation of two posters at the American College of Neuropsychopharmacology (“ACNP...
Themefolio
Profiler
Peergroup
Swarmalpha i/o · The Event Futures Prediction X
20.10.2025
© Globe Newswire
10.12.2024
ISIN: US52490G1022
Legend Biotech Corp
LEGN
LISTED
NASDAQ
CARVYKTI® Significantly Improved Minimal Residual Disease Negativity Compared to Standard of Care for Patients with Relapsed or Refractory Multiple Myeloma
Article
News Preview
SOMERSET, N.J., Dec. 09, 2024 (GLOBE NEWSWIRE) -- Legend Biotech Corporation (NASDAQ: LEGN) (Legend Biotech), a global leader in cell therapy, announced today new results from the Phase 3 CARTITUDE-4 study that show a single infusion of CARVYKTI® (ciltacabtagene autoleucel; cilta-cel) provided significantly higher rates of minimal residual diseas...
Themefolio
Profiler
Peergroup
© Globe Newswire
10.12.2024
ISIN: US05280R1005
Autolus Therapeutics plc
AUTL
LISTED
NASDAQ
Autolus Therapeutics Presents Clinical Data Updates at the American Society of Hematology (ASH) Annual Meeting 2024
Article
News Preview
Autolus Therapeutics Presents Clinical Data Updates at the American Society of Hematology (ASH) Annual Meeting 2024...
Themefolio
Profiler
Peergroup
© Globe Newswire
09.12.2024
ISIN: US75629V1044
Recursion Pharmaceuticals Inc
RXRX
LISTED
NASDAQ
Recursion Reports Interim Phase 1 Clinical Data for REC-617 Monotherapy, a Potential Best-in-Class CDK7 Inhibitor, With Encouraging Patient Response and Favorable Tolerability
Article
News Preview
SALT LAKE CITY, Dec. 09, 2024 (GLOBE NEWSWIRE) -- Recursion (Nasdaq: RXRX) reported initial monotherapy dose-escalation data from the Phase 1/2 study (ELUCIDATE) of REC-617, a selective CDK7 inhibitor, in advanced solid tumors....
Themefolio
Profiler
Peergroup
© Globe Newswire
09.12.2024
ISIN: FR0014008VX5
Euroapi S.A.
EAPI
LISTED
EURONEXT
EUROAPI moves into a new chapter with new Governance and Leadership 
Article
News Preview
Paris – December 9, 2024 – With FOCUS-27 strategic plan foundations established and its financing secured, EUROAPI moves into a new chapter. The company’s Board of Directors has accepted today the resignation of Viviane Monges as Director and Chair of the Board and Ludwig de Mot as Chief Executive Officer. Consequently, upon the recommendation of t...
Themefolio
Profiler
Peergroup
© Globe Newswire
09.12.2024
ISIN: DK0010272202
Genmab A/S
GMAB
LISTED
CPH
Two Data Analyses from Clinical Trials Show Epcoritamab (DuoBody® CD3xCD20) Induces Durable, Complete Responses as Monotherapy and Combination Treatment in Patients With Diffuse Large B-Cell Lymphoma (DLBCL)
Article
News Preview
Media ReleaseCOPENHAGEN, Denmark; December 9, 2024...
Themefolio
Profiler
Peergroup
© Globe Newswire
09.12.2024
ISIN: SE0002190926
Karolinska Development AB
KDEV
LISTED
STO
Karolinska Development's portfolio company Modus Therapeutics initiates a phase 2 study with sevuparin for treatment of chronic kidney disease with anemia
Article
News Preview
STOCKHOLM, SWEDEN – December 9, 2024. Karolinska Development AB (Nasdaq Stockholm: KDEV) today announces that its portfolio company, Modus Therapeutics, has dosed the first patient in a phase 2 clinical study of the drug candidate sevuparin, evaluated as a treatment for chronic kidney disease with anemia. The study is being conducted at Centro Rice...
Themefolio
Profiler
Peergroup
© PR Newswire
09.12.2024
ISIN: SE0022419784
Sectra AB
SECT_B
LISTED
STO
Norwegian healthcare region expands enterprise imaging contract with Sectra--digitizes pathology diagnostics to improve cancer care
Article
News Preview
LINKÖPING, Sweden, Dec. 9, 2024 /PRNewswire/ -- International medical imaging IT and cybersecurity company Sectra (STO: SECT B) announces that the Norwegian healthcare region Helse Nord RHF will expand its usage of Sectra's enterprise imaging solution to include digital pathology. The digital workflow will make it easier for pathologists to revie...
Themefolio
Profiler
Peergroup
© PR Newswire
09.12.2024
ISIN: SE0006091997
Immunovia AB (publ)
IMMNOV
LISTED
STO
Immunovia announces positive outcome and strong accuracy in the clinical validation of its next-generation test for pancreatic cancer
Article
News Preview
LUND, Sweden, Dec. 9, 2024 /PRNewswire/ -- Immunovia (STO: IMMNOV), the pancreatic cancer diagnostics company, today announces the successful completion of the CLARITI study, (Clinical Validation of Next-Generation Test for Early-Stage Pancreatic Cancer) to detect early-stage pancreatic ductal adenocarcinoma (PDAC). In the study of over 1,000 pa...
Themefolio
Profiler
Peergroup
Advertisment
20.10.2025
© EQS Newswire
09.12.2024
ISIN: DE000A1EWVY8
Formycon AG
FYB
LISTED
XETR
MS Pharma wird Kommerzialisierungspartner für FYB202 / Ustekinumab in der MENA-Region
Article
News Preview
Pressemitteilung // 09. Dezember 2024   MS Pharma wird Kommerzialisierungspartner für FYB202 / Ustekinumab in der MENA-Region Planegg-Martinsried, Amman, Jordanien – Die Formycon AG (FWB: FYB, Prime Standard, "Formycon" oder "Gesellschaft") und MS Pharma geben gemeinsam bekannt, dass sie eine Lizenz- und Liefervereinbarung für die Vermarktung von......
Themefolio
Profiler
Peergroup
© EQS Newswire
09.12.2024
ISIN: DE000A1EWVY8
Formycon AG
FYB
LISTED
XETR
MS Pharma becomes Partner for the Commercialization of FYB202 / ustekinumab in the MENA Region
Article
News Preview
Presse Release // December 09, 2024   MS Pharma becomes Partner for the Commercialization of FYB202 / ustekinumab in the MENA Region Planegg-Martinsried, Germany / Amman, Jodan – Formycon AG (FSE: FYB, Prime Standard) and MS Pharma jointly announce that they have entered into a licensing and supply agreement for the commercialization of FYB202, F......
Themefolio
Profiler
Peergroup
© BusinessWire
08.12.2024
ISIN: US09609G2093
bluebird bio, Inc.
BLUE
LISTED
NASDAQ
bluebird bio Presents Positive Long-Term Data On LYFGENIA™ (lovotobegligene autotemcel) Gene Therapy for Sickle Cell Disease at 66th American Society of Hematology (ASH) Annual Meeting and Exposition
Article
News Preview
bluebird bio, Inc. (Nasdaq: BLUE) today announced new and updated data from LYFGENIA™ (lovotobegligene autotemcel, or lovo-cel) gene therapy for patients with sickle cell disease who have a history of vaso-occlusive events (VOEs). The data will be presented at the 66th American Society of Hematology (ASH) Annual Meeting and Exposition in an oral p...
Themefolio
Profiler
Peergroup
© Globe Newswire
08.12.2024
ISIN: DK0010272202
Genmab A/S
GMAB
LISTED
CPH
Investigational Epcoritamab (DuoBody® CD3xCD20) Monotherapy Achieves High Overall and Complete Response Rates in Clinical Trial of Patients With Relapsed or Refractory (R/R) Chronic Lymphocytic Leukemia (CLL) in Preliminary Analysis
Article
News Preview
Media ReleaseCOPENHAGEN, Denmark; December 8, 2024...
Themefolio
Profiler
Peergroup
© Globe Newswire
08.12.2024
ISIN: DK0010272202
Genmab A/S
GMAB
LISTED
CPH
Investigational Epcoritamab (DuoBody® CD3xCD20) Combination Therapy Demonstrates High Response Rates in Clinical Trial of Patients With Relapsed or Refractory (R/R) Follicular Lymphoma (FL)
Article
News Preview
Media ReleaseCOPENHAGEN, Denmark; December 7, 2024...
Themefolio
Profiler
Peergroup
© BusinessWire
07.12.2024
ISIN: US09609G2093
bluebird bio, Inc.
BLUE
LISTED
NASDAQ
Long-Term Follow-Up Data Continue to Support Beti-Cel as a Potentially Curative Gene Therapy for β-Thalassemia Patients Who Require Regular Transfusions Through Achievement of Durable Transfusion Independence and Normal or Near-Normal Adult Hb Levels
Article
News Preview
bluebird bio, Inc. (Nasdaq: BLUE) today announced updated data from patients with beta-thalassemia who require regular blood transfusions treated with betibeglogene autotemcel (beti-cel, approved commercially as ZYNTEGLO™) in clinical studies. The data was presented today at the 66th American Society of Hematology (ASH) Annual Meeting and Expositi...
Themefolio
Profiler
Peergroup
© Globe Newswire
07.12.2024
ISIN: BE0003818359
Galapagos NV
GLPG
LISTED
EURONEXT
Galapagos Announces Encouraging New Results from Ongoing Phase 1/2 Study of CD19 CAR T-Cell Therapy, GLPG5101, in Patients with Relapsed/Refractory Non-Hodgkin Lymphoma
Article
News Preview
Mechelen, Belgium; December 7, 2024, 18:30 CET; Galapagos NV (Euronext & NASDAQ: GLPG) today announced additional data from the ongoing Phase 1/2 ATALANTA-1 study of its CD19 CAR T-cell therapy, GLPG5101. The results, featured in an oral presentation at the 66th American Society of Hematology (ASH) Annual Meeting and Exposition, demonstrate an...
Themefolio
Profiler
Peergroup
© Globe Newswire
06.12.2024
ISIN: BE0003766806
Ion Beam Applications SA
IBAB
LISTED
EURONEXT
NOTICE OF A GENERAL MEETING OF IBA SA
Article
News Preview
NOTICE OF A GENERAL MEETING OF IBA SA...
Themefolio
Profiler
Peergroup
© Globe Newswire
06.12.2024
ISIN: BE0003766806
Ion Beam Applications SA
IBAB
LISTED
EURONEXT
IBA - Information réglementée
Article
News Preview
 structure actionnariat 20241206.pdf structure actionnariat 20241206.pdfIBA SA – Information réglementée...
Themefolio
Profiler
Peergroup
© EQS Newswire
06.12.2024
ISIN: DE0007165631
Sartorius AG
SRT3
LISTED
XETR
Michael Grosse to succeed Joachim Kreuzburg as Chief Executive Officer of Sartorius AG
Article
News Preview
Göttingen, December 6, 2024 Michael Grosse to succeed Joachim Kreuzburg as Chief Executive Officer of Sartorius AG   Grosse to take over as Group CEO on July 1, 2025 At its meeting today, the Supervisory Board of Sartorius AG appointed Dr. Michael Grosse Chief Executive Officer of Sartorius. He will take over this position on July 1, 2025, from D......
Themefolio
Profiler
Peergroup
© EQS Newswire
06.12.2024
ISIN: DE0007165631
Sartorius AG
SRT3
LISTED
XETR
Michael Grosse folgt auf Joachim Kreuzburg als Vorstandsvorsitzender der Sartorius AG
Article
News Preview
Göttingen, 6. Dezember 2024 Michael Grosse folgt auf Joachim Kreuzburg als Vorstandsvorsitzender der Sartorius AG   Grosse wird Konzernleitung zum 1. Juli 2025 übernehmen Der Aufsichtsrat der Sartorius AG hat in seiner heutigen Sitzung Dr. Michael Grosse zum künftigen Vorstandsvorsitzenden des Konzerns ernannt. Er wird diese Aufgabe am 1. Juli ......
Themefolio
Profiler
Peergroup
© EQS Newswire
06.12.2024
ISIN: DE0007165631
Sartorius AG
SRT3
LISTED
XETR
Michael Grosse wird Vorstandsvorsitzender der Sartorius AG
Article
News Preview
Veröffentlichung einer Insiderinformation gemäß Artikel 17 MAR Michael Grosse wird Vorstandsvorsitzender der Sartorius AG Der Aufsichtsrat der Sartorius AG hat in seiner heutigen Sitzung die Bestellung von Dr. Michael Grosse zum Mitglied des Vorstands und Vorstandsvorsitzenden (CEO) der Gesellschaft mit Wirkung zum 1. Juli 2025 und einer Laufzeit v......
Themefolio
Profiler
Peergroup
© EQS Newswire
06.12.2024
ISIN: DE0007165631
Sartorius AG
SRT3
LISTED
XETR
Michael Grosse to become Chief Executive Officer of Sartorius AG
Article
News Preview
Disclosure of inside information according to Article 17 MAR Michael Grosse to become Chief Executive Officer of Sartorius AG At its meeting today, the Supervisory Board of Sartorius AG resolved to appoint Dr. Michael Grosse as member of the Executive Board and Chief Executive Officer of the company with effect from July 1, 2025, for a term of th......
Themefolio
Profiler
Peergroup
© PR Newswire
05.12.2024
ISIN: SE0002148817
Hansa Biopharma AB
HNSA
LISTED
STO
Hansa Biopharma Completes Enrolment in Global Pivotal Phase 3 Trial of imlifidase in Anti-Glomerular Basement Membrane Disease
Article
News Preview
Data from the trial is expected to be shared in 2025 LUND, Sweden, Dec. 5, 2024 /PRNewswire/ -- Hansa Biopharma, "Hansa" (Nasdaq Stockholm: HNSA) today announced it has completed the enrolment of patients in the GOOD-IDES-02 trial, a global pivotal Phase 3 trial in anti-glomerular basement membrane (anti-GBM) disease. Anti-GBM is a rare, severe a...
Themefolio
Profiler
Peergroup
© PR Newswire
05.12.2024
ISIN: SE0002148817
Hansa Biopharma AB
HNSA
LISTED
STO
Hansa Biopharma Completes Enrolment in Global Pivotal Phase 3 Trial of imlifidase in Anti-Glomerular Basement Membrane Disease
Article
News Preview
Data from the trial is expected to be shared in 2025 LUND, Sweden, Dec. 5, 2024 /PRNewswire/ -- Hansa Biopharma, "Hansa" (Nasdaq Stockholm: HNSA) today announced it has completed the enrolment of patients in the GOOD-IDES-02 trial, a global pivotal Phase 3 trial in anti-glomerular basement membrane (anti-GBM) disease. Anti-GBM is a rare, severe a...
Themefolio
Profiler
Peergroup
© Globe Newswire
05.12.2024
ISIN: DK0060448595
Coloplast A/S
COLO B
LISTED
CPH
Coloplast A/S - Decisions at the Annual General Meeting 2024
Article
News Preview
Today, 5 December 2024, Coloplast A/S held its Annual General Meeting, at which the following resolutions were adopted:...
Themefolio
Profiler
Peergroup
© BusinessWire
05.12.2024
ISIN: GB00BYMT0J19
LivaNova PLC
LIVN
LISTED
NASDAQ
LivaNova to Present Scientific Data at American Epilepsy Society 2024 Annual Meeting
Article
News Preview
LivaNova PLC (Nasdaq: LIVN), a market-leading medical technology company, today announced its participation in the American Epilepsy Society (AES) 2024 Annual Meeting, taking place December 6-10 in Los Angeles. The Company’s therapies and technologies for drug-resistant epilepsy treatment will be featured in numerous scientific posters to support...
Themefolio
Profiler
Peergroup
© BusinessWire
05.12.2024
ISIN: IE0005711209
ICON PLC
ICLR
LISTED
NASDAQ
ICON Survey Highlights Sustained Investment in AI and Digital R&D Innovation, Tempered by Siloed Adoption
Article
News Preview
ICON plc, (NASDAQ: ICLR) a world-leading clinical research organisation powered by healthcare intelligence, today announced results from a recent global survey of 101 biotech and pharma professionals across Europe and North America to understand the trajectory of AI and digital innovation adoption within clinical research. Respondents revealed t...
Themefolio
Profiler
Peergroup
© BusinessWire
05.12.2024
ISIN: CA60255C8850
Definium Therapeutics, Inc.
DFTX
LISTED
NASDAQ
MindMed Awarded Innovation Passport Designation by the United Kingdom (UK) Innovative Licensing and Access Pathway (ILAP) Steering Group for MM120 Orally Disintegrating Tablet (ODT) for Generalized Anxiety Disorder (GAD)
Article
News Preview
Mind Medicine (MindMed) Inc. (NASDAQ: MNMD), (the "Company" or "MindMed"), a clinical-stage biopharmaceutical company developing novel product candidates to treat brain health disorders, today announced that MM120 ODT, a pharmaceutically optimized form of lysergide D-tartrate (LSD), has been granted an Innovation Passport for the potential treatme...
Themefolio
Profiler
Peergroup
© EQS Newswire
05.12.2024
ISIN: DE000A1EWVY8
Formycon AG
FYB
LISTED
XETR
Formycon steigt in den SDAX der Deutschen Börse auf
Article
News Preview
Pressemitteilung // 05. Dezember 2024 Formycon steigt in den SDAX der Deutschen Börse auf Formycon-Aktie gehört künftig zur DAX-Indexfamilie und zu den 70 größten deutschen Unternehmen unterhalb des MDAX Attraktivität der Aktie steigt nach kürzlich erfolgtem Uplisting in den Prime Standard Aufnahme in den Auswahlindex ab 23. Dezember 2024 wirks......
Themefolio
Profiler
Peergroup
© EQS Newswire
05.12.2024
ISIN: DE000A1EWVY8
Formycon AG
FYB
LISTED
XETR
Formycon joins the SDAX of the German Stock Exchange
Article
News Preview
Press Release // December 5, 2024 Formycon joins the SDAX of the German Stock Exchange Formycon shares will be part of the DAX index family, ranking among the 70 largest German companies below the MDAX Enhanced share attractiveness following recent uplisting to the Prime Standard Formycon shares to be included in the index effective as of Decem......
Themefolio
Profiler
Peergroup
© EQS Newswire
05.12.2024
ISIN: DE0005659700
Eckert & Ziegler SE
EUZ
LISTED
XETR
Eckert & Ziegler und Ariceum Therapeutics unterzeichnen globalen Liefervertrag für die Entwicklung von Radiotherapeutika der nächsten Generation im Bereich der präzisen Krebsbehandlung
Article
News Preview
Berlin, 5. Dezember 2024. Eckert & Ziegler, einer der weltweit größten Anbieter von Isotopen für medizinische, wissenschaftliche und industrielle Zwecke, und Ariceum Therapeutics (Ariceum), ein privates Biotech-Unternehmen, das radiopharmazeutische Produkte für die Diagnose und Therapie bestimmter schwer zu behandelnder Krebsarten entwickelt, g......
Themefolio
Profiler
Peergroup
© EQS Newswire
05.12.2024
ISIN: DE0005659700
Eckert & Ziegler SE
EUZ
LISTED
XETR
Eckert & Ziegler and Ariceum Therapeutics Sign Global Supply Agreement for the Development of Next-Generation Radiotherapeutics for Precision Cancer Treatments
Article
News Preview
Berlin, 5 December 2024. Eckert & Ziegler, one of the world’s largest providers of isotopes for medical, scientific and industrial use, and Ariceum Therapeutics (Ariceum), a private biotech company developing radiopharmaceutical products for the diagnosis and treatment of certain hard-to-treat cancers, today announced the signing of a global su......
Themefolio
Profiler
Peergroup
© PR Newswire
05.12.2024
ISIN: SE0010323311
BioArctic AB
BIOA B
LISTED
STO
First patient dosed in EXIST Phase 2a study in Parkinson's disease
Article
News Preview
STOCKHOLM  , Dec. 5, 2024 /PRNewswire/ -- BioArctic AB (publ) (Nasdaq Stockholm: BIOA B) announced today that the first patient has been dosed with exidavnemab in the EXIST Phase 2a study, in Parkinson's disease patients. Exidavnemab is a monoclonal antibody designed to target aggregated forms of the protein α-synuclein, believed to play a role i...
Themefolio
Profiler
Peergroup
© PR Newswire
05.12.2024
ISIN: SE0010323311
BioArctic AB
BIOA B
LISTED
STO
First patient dosed in EXIST Phase 2a study in Parkinson's disease
Article
News Preview
STOCKHOLM  , Dec. 5, 2024 /PRNewswire/ -- BioArctic AB (publ) (Nasdaq Stockholm: BIOA B) announced today that the first patient has been dosed with exidavnemab in the EXIST Phase 2a study, in Parkinson's disease patients. Exidavnemab is a monoclonal antibody designed to target aggregated forms of the protein α-synuclein, believed to play a role i...
Themefolio
Profiler
Peergroup
© PR Newswire
05.12.2024
ISIN: SE0010323311
BioArctic AB
BIOA B
LISTED
STO
Leqembi® approved in Mexico
Article
News Preview
STOCKHOLM, Dec. 5, 2024 /PRNewswire/ -- BioArctic AB's (publ) (Nasdaq Stockholm: BIOA B) partner Eisai today announced that the Federal Commission for the Protection Against Sanitary Risk (COFEPRIS) in Mexico has approved Leqembi (lecanemab) for the treatment of early Alzheimer's disease (AD)1.   Leqembi selectively binds to soluble amyloid-beta...
Themefolio
Profiler
Peergroup
© PR Newswire
05.12.2024
ISIN: SE0010323311
BioArctic AB
BIOA B
LISTED
STO
Leqembi® approved in Mexico
Article
News Preview
STOCKHOLM, Dec. 4, 2024 /PRNewswire/ -- BioArctic AB's (publ) (Nasdaq Stockholm: BIOA B) partner Eisai today announced that the Federal Commission for the Protection Against Sanitary Risk (COFEPRIS) in Mexico has approved Leqembi (lecanemab) for the treatment of early Alzheimer's disease (AD)1.   Leqembi selectively binds to soluble amyloid-beta...
Themefolio
Profiler
Peergroup
© BusinessWire
04.12.2024
ISIN: US09609G2093
bluebird bio, Inc.
BLUE
LISTED
NASDAQ
bluebird bio Announces 1-for-20 Reverse Stock Split
Article
News Preview
bluebird bio, Inc. (NASDAQ: BLUE) (“bluebird bio” or the “Company”) today announced that it will proceed with a 1-for-20 reverse stock split (“Reverse Stock Split”) of the Company’s common stock following approval by both its Board of Directors and BLUE stockholders at its reconvened annual meeting held on December 4, 2024. As previously announced...
Themefolio
Profiler
Peergroup
© Globe Newswire
04.12.2024
ISIN: FR0012127173
OSE Immunotherapeutics SA
OSE
LISTED
EURONEXT
OSE Immunotherapeutics : Informations Relatives au Nombre Total de Droits de Vote et d’Actions Composant le Capital
Article
News Preview
Informations Relatives au Nombre Total de Droits de Vote et d’Actions Composant le Capital...
Themefolio
Profiler
Peergroup
© BusinessWire
04.12.2024
ISIN: US09609G2093
bluebird bio, Inc.
BLUE
LISTED
NASDAQ
bluebird bio Confirms Participation in Center for Medicare and Medicaid Innovation (CMMI) Cell and Gene Therapy Access Model
Article
News Preview
bluebird bio, Inc. (NASDAQ: BLUE) (“bluebird bio”) today announced it has reached an agreement with the Center for Medicare and Medicaid Innovation to offer an outcomes-based agreement for LYFGENIA gene therapy under the Cell and Gene Therapy (CGT) Access Model. LYFGENIA is a one-time gene therapy approved for the treatment of patients 12 years of...
Themefolio
Profiler
Peergroup
© BusinessWire
04.12.2024
ISIN: US29332G1022
Enhabit Inc
EHAB
LISTED
NYSE
Delaware Court of Chancery Awards Damages and Other Relief to Encompass Health and Enhabit for Misconduct by April Anthony, Other Former Officers, and Private Equity Firms Vistria Group and Nautic Partners
Article
News Preview
On Monday, Encompass Health and Enhabit won their lawsuit in the Delaware Court of Chancery related to breaches of fiduciary duty by April Anthony, Luke James, and Chris Walker while they served as the senior officers at Encompass Health’s former home health and hospice division, which is now Enhabit. The Court awarded judgment against private equ...
Themefolio
Profiler
Peergroup
© BusinessWire
04.12.2024
ISIN: US03168L1052
Amneal Pharmaceuticals Inc
AMRX
LISTED
NASDAQ
Amneal to Participate at Upcoming Investor Conferences
Article
News Preview
Amneal Pharmaceuticals, Inc. (Nasdaq: AMRX) (“Amneal” or the “Company”), a global pharmaceutical company, announced today that Chirag Patel, Co-Chief Executive Officer and President, and Tasos Konidaris, Chief Financial Officer, will participate in two upcoming investor conferences. 36th Annual Piper Sandler Annual Healthcare Conference December...
Themefolio
Profiler
Peergroup
© BusinessWire
04.12.2024
ISIN: CA23256X4075
Cybin Inc.
HELP
LISTED
NASDAQ
Cybin to Participate in Water Tower Research Fireside Chat on December 11, 2024
Article
News Preview
Cybin Inc. (NYSE American:CYBN) (Cboe CA:CYBN) (“Cybin” or the “Company”), a clinical-stage breakthrough neuropsychiatry company committed to revolutionizing mental healthcare by developing new and innovative next-generation treatment options, is pleased to announce that Doug Drysdale, Cybin’s Chief Executive Officer, and Amir Inamdar, MBBS, DNB (...
Themefolio
Profiler
Peergroup
© Globe Newswire
04.12.2024
ISIN: DK0060448595
Coloplast A/S
COLO B
LISTED
CPH
Coloplast divests core Skin Care product portfolio
Article
News Preview
The divestment is part of a strategic initiative to simplify business operations and improve profitability in the Advanced Wound Care business area....
Themefolio
Profiler
Peergroup
© EQS Newswire
04.12.2024
ISIN: DE000A3ENQ51
SCHOTT Pharma AG & Co KgaA
1SXP
LISTED
XETR
SCHOTT Pharma unveils innovative nest design for ready-to-use cartridges
Article
News Preview
Next-level efficiency and sustainability: SCHOTT Pharma unveils innovative nest design for ready-to-use cartridges New diamond-shaped nest design for ready-to-use (RTU) cartridges boosts efficiency in pharmaceutical filling processes by up to 67% and significantly reduces CO2 emissions by close to 25% in the supply chain for 1.5 ml RTU cartridges......
Themefolio
Profiler
Peergroup
© EQS Newswire
04.12.2024
ISIN: DE000A3ENQ51
SCHOTT Pharma AG & Co KgaA
1SXP
LISTED
XETR
SCHOTT Pharma präsentiert innovatives Nestdesign für vorsterilisierte Karpulen
Article
News Preview
Effizient und nachhaltig: SCHOTT Pharma präsentiert innovatives Nestdesign für vorsterilisierte Karpulen Neues rautenförmiges Nest für vorsterilisierte, ready-to-use (RTU)-Karpulen steigert die Effizienz von pharmazeutischen Abfüllprozessen um bis zu 67% und reduziert die CO2-Emissionen in der Lieferkette um beinahe 25% für 1,5 ml Karpulen. Je na......
Themefolio
Profiler
Peergroup
© Globe Newswire
03.12.2024
ISIN: DK0010272202
Genmab A/S
GMAB
LISTED
CPH
Capital Increase in Genmab as a Result of Employee Warrant Exercise
Article
News Preview
Company Announcement...
Themefolio
Profiler
Peergroup
© Globe Newswire
03.12.2024
ISIN: IE000LK2BOB4
Mural Oncology PLC
MURA
LISTED
NASDAQ
Mural Oncology Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Article
News Preview
WALTHAM, Mass and DUBLIN, Dec. 03, 2024 (GLOBE NEWSWIRE) -- Mural Oncology plc (Nasdaq: MURA), a clinical-stage immuno-oncology company developing novel, investigational engineered cytokine therapies designed to address areas of unmet need for patients with a variety of cancers, today announced that on December 2, the Company granted to four newl...
Themefolio
Profiler
Peergroup
© Globe Newswire
03.12.2024
ISIN: DK0060055861
Chemometec A/S
CHEMM
LISTED
CPH
Upgrade of revenue and operating profit guidance
Article
News Preview
ANNOUNCEMENT NO. 285...
Themefolio
Profiler
Peergroup
© EQS Newswire
03.12.2024
ISIN: DE0005659700
Eckert & Ziegler SE
EUZ
LISTED
XETR
Changes in the Executive Board and Supervisory Board
Article
News Preview
Berlin, 3 December 2024. The Supervisory Board of Eckert & Ziegler SE has appointed Dr. Gunnar Mann (57) as a new member of the Executive Board, effective 1 January 2025. He will assume operational responsibility for the Medical segment. Dr. Mann who holds a doctorate in physics, joined Eckert & Ziegler in 1998 and initially started as head......
Themefolio
Profiler
Peergroup
© EQS Newswire
03.12.2024
ISIN: DE0005659700
Eckert & Ziegler SE
EUZ
LISTED
XETR
Wechsel in Vorstand und Aufsichtsrat
Article
News Preview
Berlin, 3. Dezember 2024. Der Aufsichtsrat der Eckert & Ziegler SE hat Dr. Gunnar Mann (57) mit Wirkung zum 1.1.2025 als neues Vorstandsmitglied bestellt. Er wird die operative Verantwortung für das Segment Medical übernehmen. Der promovierte Physiker kam 1998 zu Eckert & Ziegler und startete zunächst als Entwicklungsleiter. Danach war er a......
Themefolio
Profiler
Peergroup
© BusinessWire
03.12.2024
ISIN: CA60255C8850
Definium Therapeutics, Inc.
DFTX
LISTED
NASDAQ
MindMed Appoints Javier Muniz, M.D., as Vice President of Research and Development Strategy
Article
News Preview
Mind Medicine (MindMed) Inc. (NASDAQ: MNMD), (the "Company" or "MindMed"), a clinical-stage biopharmaceutical company developing novel product candidates to treat brain health disorders, today announced the appointment of Javier A. Muniz, M.D., as Vice President of Research and Development (R&D) Strategy. In his new role, Dr. Muniz will drive...
Themefolio
Profiler
Peergroup
© Globe Newswire
03.12.2024
ISIN: DK0010272202
Genmab A/S
GMAB
LISTED
CPH
Transactions With Shares and Linked Securities in Genmab A/S Made by Managerial Employees and Their Closely Associated Persons
Article
News Preview
Company Announcement...
Themefolio
Profiler
Peergroup
© PR Newswire
03.12.2024
ISIN: SE0011205202
Vitrolife AB
VITR
LISTED
STO
Patrik Tolf steps down as CFO of the Vitrolife Group - Helena Wennerström appointed acting CFO
Article
News Preview
GOTHENBURG, Sweden, Dec. 3, 2024 /PRNewswire/ -- Vitrolife AB (publ) announces today that Patrik Tolf will be stepping down as Chief Financial Officer due to personal reasons. Helena Wennerström will assume the role of acting CFO. Helena has extensive experience in finance and business management, including having served as CFO at ViaCon Group AB...
Themefolio
Profiler
Peergroup
© PR Newswire
03.12.2024
ISIN: SE0002148817
Hansa Biopharma AB
HNSA
LISTED
STO
Genethon and Hansa Biopharma announce initiation of a Phase 2 trial of imlifidase as a pre-treatment to GNT-0003 in severe Crigler-Najjar syndrome
Article
News Preview
The trial will be conducted in patients with pre-existing anti-AAV antibodies which limit use of gene therapy treatment. LUND, Sweden and EVRY, France, Dec. 3, 2024 /PRNewswire/ -- Hansa Biopharma, "Hansa" (Nasdaq Stockholm: HNSA) and Genethon, a pioneer and a leader in gene therapy research and development for rare genetic diseases, today announ...
Themefolio
Profiler
Peergroup
© PR Newswire
03.12.2024
ISIN: SE0002148817
Hansa Biopharma AB
HNSA
LISTED
STO
Genethon and Hansa Biopharma announce initiation of a Phase 2 trial of imlifidase as a pre-treatment to GNT-0003 in severe Crigler-Najjar syndrome
Article
News Preview
The trial will be conducted in patients with pre-existing anti-AAV antibodies which limit use of gene therapy treatment. LUND, Sweden and EVRY, France, Dec. 3, 2024 /PRNewswire/ -- Hansa Biopharma, "Hansa" (Nasdaq Stockholm: HNSA) and Genethon, a pioneer and a leader in gene therapy research and development for rare genetic diseases, today announ...
Themefolio
Profiler
Peergroup
© Globe Newswire
03.12.2024
ISIN: US45258D1054
Immunocore Holdings plc
IMCR
LISTED
NASDAQ
Immunocore announces reimbursement agreement in England for KIMMTRAK▼ for the treatment of HLA-A*02:01-positive adults with unresectable or metastatic uveal melanoma
Article
News Preview
Immunocore announces reimbursement agreement in England for KIMMTRAK▼ for the treatment of HLA-A*02:01-positive adults with unresectable or metastatic uveal melanoma...
Themefolio
Profiler
Peergroup
© Globe Newswire
02.12.2024
ISIN: FR0012127173
OSE Immunotherapeutics SA
OSE
LISTED
EURONEXT
OSE Immunotherapeutics Strengthens Leadership and Executive Committee
Article
News Preview
OSE Immunotherapeutics Strengthens Leadership and Executive Committee...
Themefolio
Profiler
Peergroup
Long/Short | Fractionals | Margin | Hedge · 4 powerful Trading App | MT4.MT5.ACTIVTRADER | TradingViewplus
Indices
DAX, DOW, S&P, FTSE...
Realtime Trading
With & without leverage
Currencies
EUR, USD, JPY, BRL, GBP ....
50 FX-Pairs
Top Conditions, Tied spreads, Mini/Micro
Commodities
Brent, WTI, Coffee, Wheat....
Long & Short
Crude oil, Agricultural & more
Metals
Gold, Silver, Palladium, Platinum
Hedging
Soft-,Heavy-, Precious Metals
Stocks & ETF
TSLA, NFLX, NVDA, MSFT, AAPL ....
Leveraged Equity Trading
USA, Europe, Asia
More information, click here

More sector specific news

Your Press Release is missing or you want share news over GICS11? Drop us a line.

Gamechanger in online marketing · Innovation as a service · Upgrade your own internet presence.

XLB
XLE
XLU
XLY
XLF
XLP
XLV
XLK
XLC
XLI
XLRE
© 2026 Select Sector SPDRs
* * *
More Sector related Investment Ideas
XLB
XLE
XLU
XLY
XLF
XLP
XLV
XLK
XLC
XLI
XLRE
© 2026 WEBs Investments ETFs
About the newsfeed
#1
What types of information are provided on this portal - and what purpose does it serve?
The portal provides structured, stock market-relevant company information that is specifically assigned to a particular economic sector. The focus is on current announcements from official NewsWire sources, supplemented by company profiles, filter options by sector and sector-specific research aids. The aim is to offer an interested group of people a systematically structured research environment that improves their understanding of sector developments and corporate strategies.
#2
Why are companies categorized according to a certain system?
Financial markets consist of thousands of listed companies with very different business models. In order to create transparency and comparability, companies worldwide are assigned to standardized classifications. These classifications help investors to better analyze markets, identify sector-specific trends and make more targeted investment decisions.
#3
What classification standards exist for grouping companies?
There are various industry classifications that are used depending on the region or application. The best known include GICS (Global Industry Classification Standard), ICB (Industry Classification Benchmark), NAICS (North American Industry Classification System) and TRBC (Thomson Reuters Business Classification). Most institutional investors and ETFs worldwide use GICS or ICB as a benchmark.
#4
What classification standard is this financial information portal based on?
The portal uses the Global Industry Classification Standard (GICS), which was jointly developed by MSCI and S&P Dow Jones Indices. GICS is widely used in the institutional financial world and forms the basis for many global equity indices, ETFs and research systems.
#5
What exactly does GICS mean - and how is the system structured?
GICS stands for Global Industry Classification Standard. It is a hierarchical structure that divides listed companies worldwide into four levels: Sector, Industry Group, Industry Sector and Sub-Industry. In total, the system comprises 11 main sectors, over 60 industries and more than 150 sub-categories. It allows a consistent, internationally comparable analysis of economic activities.
#6
Why is GICS important in the financial world?
GICS offers a standardized language for investment decisions. It makes it possible to compare companies with similar business models - regardless of country, stock exchange or company size. Many investment funds, indices and research houses use GICS as a basis for portfolio construction, risk analysis or market screening. This means that it also makes sense for private investors to use this structure as a guide.
#7
Who decides which GICS sector a company is assigned to?
The allocation is made by the index providers MSCI and S&P Dow Jones on the basis of a company's main business segment. The decisive factor is the segment from which the company generates the majority of its sales or operating profit. Changes in the business model or strategic realignments can lead to a company being assigned to a different industry or even a different sector.
#8
What is meant by the GICS sector "Materials"?

The GICS "Materials" sector comprises companies that are active in the production, processing or refinement of raw materials. This includes industries such as chemicals, building materials, paper & forest products and the entire metallurgical and mining industry. The sector is highly cyclical and is particularly sensitive to economic fluctuations and changes in global demand.

#9
Which companies typically belong to the Materials sector?
Typical representatives are international groups from the areas of chemicals production (e.g. BASF), precious metal mining (e.g. Barrick Gold), building materials production (e.g. Heidelberg Materials) or industrial gases (e.g. Linde). The shares of these companies are often heavily dependent on commodity prices and play a central role in industrial value chains.
#10
Where does the company news on this page come from?
The news is based on verified and publicly available sources such as BusinessWire, GlobeNewswire, PR Newswire, EQS, Newsfile, ACCESSNewswire and other NewsWire services. These platforms are used by listed companies to publish mandatory ad hoc announcements, financial reports or strategic developments. All content is prepared in a structured manner and, if a corresponding categorization is possible, brought together in industry-specific clusters.
#11
How is the sector-specific mapping of messages carried out?
Categorization is based on structured metadata (e.g. ISIN, ticker, sector classification) and a combination of keyword analysis and GICS mapping. This ensures that all news is assigned to the correct sector and - if available - the correct sub-sector.
#12
Why is the materials sector particularly interesting for investors?
The Materials sector is closely linked to global industrial production and offers both cyclical growth opportunities and hedging opportunities against inflation and raw material shortages. In addition, many companies in this sector play a key role in future topics such as electromobility, the energy transition and sustainable building materials.
#13
What distinguishes this project from traditional financial information portals?
In contrast to generic portals, this project focuses exclusively and specifically on a particular sector. The advantage for interested investors: Sector-specific information, news, market movements and company profiles can be filtered and analyzed in a more targeted manner. This enables more in-depth research and greater relevance for thematic investment decisions.
#14
Are smaller companies also represented here or only large corporations?
The newsfeed takes into account both large caps and mid and small caps. As a clear mapping criterion is required in order to enable the most precise possible allocation to a cluster, the ISIN of the listed company is generally used for this purpose, provided that this can be made available or mapped via corresponding newsfeed parameters.
#15
How up-to-date are the displayed messages?
The content is updated regularly. The publication follows the publications of the information source, the NewsWire feeds of the underlying distributors. Incoming reports are automatically processed, classified and displayed on the page. Timestamps and source information ensure maximum transparency.
#16
Can I also filter the news by sub-sector?
Yes, this is a central feature of the site. Within a main sector, you can filter specifically for sub-sectors such as "Metals & Mining". For particularly popular industries or developments within a meta-sector, it is possible to deviate from standard clusters. Special categories with particular information value enable thematic analyses to be carried out even more precisely.
#17
Are there plans to process other metasectors in a similar way?
Yes, this financial information portal is part of an extensive project in which separate information portals are being created for all the main sectors. The aim is to provide investors with a systematic, sector-based research tool - regardless of index affiliation or provider perspective.
#18
Why do companies publish announcements via NewsWire services at all?
NewsWire services such as BusinessWire or PR Newswire fulfill a regulatory function: they enable companies to publish price-sensitive information publicly and without discrimination. In many countries, the use of such services is a prerequisite for fulfilling publication obligations under capital market law. They also enable companies to reach the media, analysts and investors in a targeted manner.
#19
Can private or inactive companies also appear in such notifications?
Generally not. The platform focuses exclusively on listed companies whose disclosures are based on regulatory requirements or corporate strategy measures. Although private or unlisted companies occasionally publish announcements, these are not systematically processed or classified here.
#20
What happens when a company changes its business model - does its sector classification also change?
Yes, as a rule - but not automatically. The responsible classification institutes (e.g. MSCI and S&P for GICS) regularly check the relevance and consistency of the classifications. If there is a significant change in a company's sales or profit profile, it may be reclassified to a different industry or even a different sector. This usually takes place after fixed review cycles or upon request.
#21
How is it ensured that a company is correctly categorized if it is active in several business areas?
The categorization is based on the dominant sales segment. If a company is active in several sectors but generates 70% of its turnover with chemical products, for example, it is assigned to the GICS sector "Materials" - even if it also has activities in the energy or transportation sector. In borderline cases, additional qualitative assessment criteria apply.
#22
Are there any legal risks in the further use of the displayed content?
The content comes from public sources, but is partially subject to copyright protection - particularly with regard to text structure and layout. The excerpts and links provided on this portal are made within the scope of permitted use (e.g. right to quote or editorial processing). However, commercial use by third parties is not permitted without the express permission of the original providers.
#23
Who can I contact if I have general questions or legal concerns?
A central contact point is available for general inquiries, information on company recordings, compliance issues or copyright-relevant aspects. In rare cases, for example in the case of erroneously published information or justified requests for deletion, a review and, if necessary, removal from the public feed can take place. Please only use the official contact option in the legal notice or at the bottom of the page.
#24
Is advertising or third-party content also displayed on the portal?
Yes, in defined areas the portal can display advertising content or product-specific information from third parties - for example on sector-related financial services, research offers or trading platforms. This content is clearly marked as advertising or partner information and is separate from the editorial or automatically processed company news.
#26
Can I give feedback on the platform or submit suggestions?
Absolutely - feedback is expressly welcome. The platform is an open information service that is continuously being developed. Comments on functionality, data quality, usability or thematic extensions help to optimize the service for the benefit of users. You can submit your suggestions informally via the contact page or special feedback forms.
#27
I am an information provider - can I cooperate with the portal?
Yes, the portal is open to content-related, technical or editorial cooperation, provided that this contributes to the quality, relevance or dissemination of the offering. If you offer content, interfaces or services that could be useful in the context of stock market-related information, we would be pleased to hear from you. The platform offers flexible integration options and a professional environment for quality-assured content.
#28
Can the platform technology also be used for other applications or partners?
Yes, the platform is based on a modular, scalable infrastructure that can be adapted to different information contexts and industry models. Technical components such as data aggregation, structuring logic, classification mechanisms and semantic filters can also be made available for external projects or individual applications on request. Please contact us for cooperation or license models.
#29
Can the underlying company data also be licensed or reused?
Structured access to selected master data of listed companies - such as GICS mapping, ISIN mapping, news feeds or metadata filters - is generally possible. The offer is aimed in particular at information service providers, research platforms or data-driven financial applications. Data can be provided via defined interfaces (e.g. API) or exportable formats, depending on the intended use and license framework.
#30
What forms of cooperation with external partners are conceivable?
Basically open. Possible forms of cooperation range from technical integrations and shared data models to content syndication or white label solutions. Partnerships with institutions that are looking for access to quality-assured data, dynamically structured news or sector-specific analyses - for example in the FinTech, media or research environment - are particularly interesting. We look forward to hearing from business development or product management departments.
#31
Why does this portal differ technically and conceptually from other information offerings?
Because no one from outside the industry is trying to understand the financial market here - but because the know-how comes from the heart of the financial world. The technical platform was developed by a team that combines in-depth market knowledge with innovative system design. The result: information architecture with real relevance, not shop window technology.
#32
What makes the technical solution particularly interesting for operators of their own financial portals?
In addition to high adaptability, the platform impresses with its modular structure and the consistent implementation of industry-specific logic - from GICS mapping to metadata filtering. For providers who operate their own information portals, sector-specific data structures, news feeds or visualizations can be quickly integrated on this basis - either as a white label, API module or embedded solution.
#33
Why can a collaboration go beyond traditional development services?
Because we don't just program, we think: The technological implementation is based on a deep understanding of market cycles, regulations, data formats and investor needs. Anyone who cooperates with this platform benefits from a sparring partner at eye level - both technically and professionally. This creates added value that goes far beyond pure IT expertise.
#34
Note on copyright and the processing of original content
The corporate news presented on this information portal is based on publicly accessible sources such as BusinessWire, GlobeNewswire, PR Newswire or comparable news services. The content is processed as part of an automated or editorially supported structuring process without changing, shortening or reinterpreting the content of the original information. This is so-called "as is" information, the form and content of which corresponds to the originally published announcement. The rights to the original texts remain unrestrictedly with the respective publishers or copyright holders. This portal merely assumes a structural categorization and allocation within the framework of a news-journalistic offer. Independent commercial reuse, systematic reproduction or other use of the content by third parties is only permitted within the framework of the statutory provisions or with the consent of the copyright holder.
About GICS Health
GICS Health is part of the GICS Eleven information portfolio, which focuses primarily on information from listed companies in the health sector. The sector classification serves as a guide to navigate quickly and conveniently through the latest industry-specific news. Individual peer group clusters complement the news offering.
About GICS Eleven

GICS Eleven (G11, GICS11) bundles topic-specific content and enables quick access to relevant information thanks to its gate function. The project is largely based on the Global Industry Classification Standard (GICS®), which was developed by MSCI and Standard & Poor's and enables a breakdown into sectors. GICS® consists of 11 sectors, 24 industry branches, 69 industries and 158 sub-industries.

GICS® is a registered trademark of MSCI Inc. and S&P Dow Jones Indices.

Member of 3R/RSQ Network
Digital Content
Network Alliance
Transparency - Reliability - Credibility
Information regarding Product Information
Wednesday, 21.01.2026, Calendar Week 04, 21st day of the year, 344 days remaining until EoY.